Literature DB >> 24384882

Feasibility of home infusion and self-administration of nanofiltered C1 esterase inhibitor for routine prophylaxis in patients with hereditary angioedema and characterization of a training and support program.

Cherylann Gregory1, Ladonna M Landmesser, Larry Corrigan, David Mariano.   

Abstract

Hereditary angioedema (HAE) is a rare, chronic disease of C1 inhibitor deficiency. Study researchers evaluated the prevalence of home and self-administration of nanofiltered, human-derived C1 esterase inhibitor infusions and the implementation of a nursing training and support program. Home administration rate increased from 49.0% to 75.8%. The percentage who self-administered increased from 20.3% to 43.9%. Doses per week averaged 1.85 at home compared with 1.40 in infusion centers and physicians' offices. Patients required an average of 5 visits to be trained. Self-administration is a viable, feasible option in the management of HAE, which is facilitated by a nurse-managed training and support program.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24384882     DOI: 10.1097/NAN.0000000000000018

Source DB:  PubMed          Journal:  J Infus Nurs        ISSN: 1533-1458


  3 in total

1.  Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.

Authors:  Elyse Murphy; Christine Donahue; Laurel Omert; Stephanie Persons; Thomas J Tyma; Joseph Chiao; William Lumry
Journal:  Nurs Open       Date:  2018-08-28

2.  High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.

Authors:  Veronica Squeglia; Alessandro Barbarino; Maria Bova; Carmela Gravante; Angelica Petraroli; Giuseppe Spadaro; Massimo Triggiani; Arturo Genovese; Gianni Marone
Journal:  Orphanet J Rare Dis       Date:  2016-09-29       Impact factor: 4.123

Review 3.  Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance.

Authors:  Huamin Henry Li
Journal:  Patient Prefer Adherence       Date:  2016-09-07       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.